Taiwan COVID vaccine maker to apply for EUA after promising Phase II trial results
06/10/2021 05:39 PM
Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Thursday that it would seek an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate after unblinding the results of its Phase II clinical trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Taiwan wins 1st gold at World University Games in women's team poomsae
07/18/2025 08:53 PM - Sports
Corbin Carroll eyes USA's WBC team, but two others may be in on Taiwan
07/18/2025 08:20 PM - Business
Asia-Pacific telecom giants launch submarine cable to boost connectivity
07/18/2025 07:22 PM - Politics
5 more KMT lawmakers to face recall votes on Aug. 23: CEC
07/18/2025 07:08 PM - Politics
Defense chief lauds effort but acknowledges mishaps in Taiwan drills
07/18/2025 06:45 PM